The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department

Şenyurt, Mahmut; Karaşahin, Ömer; Küçükceran, Kadir; delice, orhan; şebin, engin; İba Yilmaz, Sibel; Batur, Ali

doi:10.18678/dtfd.820602

The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department

Kadir KÜÇÜKCERAN, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Acil Tıp Anabilim Dalı, Konya, Türkiye)

Ömer KARAŞAHİN, (Erzurum Bölge Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Bölümü, Erzurum, Türkiye)

Orhan DELİCE, (Erzurum Bölge Eğitim ve Araştırma Hastanesi, Acil Tıp Bölümü, Erzurum, Türkiye)

Ali BATUR, (Hacettepe Üniversitesi, Tıp Fakültesi, Acil Tıp Anabilim Dalı, Ankara, Türkiye)

Sibel İBA YILMAZ, (Erzurum Bölge Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Bölümü, Erzurum, Türkiye)

Engin ŞEBİN, (Erzurum Bölge Eğitim ve Araştırma Hastanesi, Biyokimya Bölümü, Erzurum, Türkiye)

Mahmut ŞENYURT (Erzurum Bölge Eğitim ve Araştırma Hastanesi, Biyokimya Bölümü, Erzurum, Türkiye)

Düzce Tıp Fakültesi Dergisi

3 1

Yıl: 2021 Cilt: 23 Sayı: 1 Sayfa Aralığı: 15 - 19 Metin Dili: İngilizce DOI: 10.18678/dtfd.820602 İndeks Tarihi: 14-06-2021

The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department

Öz:

Aim: The urokinase-type plasminogen activator (uPA) system consists of a protease, a receptor(urokinase-type plasminogen activator receptor, uPAR), and inhibitors that can be expressed onvarious cell types. Previous literature shows that the amount of soluble urokinase-typeplasminogen activator receptor (suPAR) secreted from affected cells is higher in Crimean-Congohemorrhagic fever (CCHF) patients than in healthy controls. Thus, we aimed to investigate thediagnostic value of suPAR in the differential diagnosis of CCHF in emergency services.Material and Methods: Individuals over 16 years old with a preliminary diagnosis of CCHFdisease were divided into two groups as real time-polymerase chain reaction (RT-PCR) and/orIgM positive (CCHF group) and RT-PCR and/or IgM negative (control group).Results: Eighty patients were included in this study. Forty patients with CCHF virus PCRand/or CCHF virus IgM were identified as CCHF group and 40 patients included as negativecontrol group. The median age of the patients was 45 (range, 16-91) years, and 49 patients(61.3%) were male. Leukocyte, platelet, and fibrinogen levels were significantly lower, whilecreatinine kinase, aPTT, and D-dimer levels were significantly higher in CCHF group. Therewas no statistically significant difference between the control group and CCHF group forSuPAR (p=0.386). In addition, control group patients not diagnosed with CCHF wereexamined, brucellosis, influenza, and pneumonia were found to be the most common.Conclusion: The use of suPAR as a biomarker in the differentiation of patients with similarfindings in emergency services was investigated and found to have no diagnostic value.

Anahtar Kelime:

Acil Serviste Kırım Kongo Kanamalı Ateş Hastalığında Soluble Ürokinaz Plazminojen Aktivatör Reseptörünün Tanısal Değeri

Öz:

Amaç: Ürokinaz tipi plazminojen aktivatör (uPA) sistemi, çeşitli hücrelerden salınan proteaz, reseptör (ürokinaz tipi plazminojen aktivatör reseptör, uPAR) ve inhibitörlerden oluşur. Literatürde, enfekte olan hücrelerden salgılanan solüble ürokinaz plazminojen aktivatör reseptörü (suPAR) düzeyinin Kırım-Kongo kanamalı ateşi (KKKA) hastalarında sağlıklı kontrollere göre daha yüksek olduğu gösterilmiştir. Bu çalışmada acil serviste KKKA'nın ayırıcı tanısında suPAR'ın tanısal değerinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: KKKA hastalığı ön tanısı alan 16 yaşın üstündeki bireyler gerçek zamanlı polimeraz zincir reaksiyonu (real time-polymerase chain reaction, RT-PCR) ve/veya IgM pozitif (KKKA grubu) ve RT-PCR ve/veya IgM negatif (kontrol grubu) olarak iki gruba ayrıldı. Bulgular: Bu çalışmaya 80 hasta dahil edildi. KKKA virus PCR ve/veya KKKA virus IGM’li 40 hasta KKKA grubu olarak ve 40 hasta negatif kontrol grup olarak belirlendi. Hastaların ortanca yaşı 45 (aralık, 16-91) yıldı ve 49 (%61,3) hasta erkekti. KKKA grubunda lökosit, trombosit ve fibrinojen seviyeleri istatistiksel anlamlı olarak düşüktü, kreatinin kinaz, aPTT ve D-dimer seviyeleri ise istatistiksel anlamlı olarak yüksekti. SuPAR için kontrol grubu ile KKKA grubu arasında istatistiksel olarak anlamlı bir farklılık yoktu (p=0.386). Ayrıca KKKA tanısı almayan kontrol grubu hastaları incelendiğinde, en sık bruselloz, influenza ve pnömoni olduğu bulundu. Sonuç: Acil serviste benzer bulgulara sahip hastaların ayırt edilmesinde bir biyobelirteç olarak suPAR'ın kullanımı araştırıldı ve tanısal değeri olmadığı bulundu.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol. 2012;2(2):215-20.
2. Al-Abri SS, Abaidani IA, Fazlalipour M, Mostafavi E, Leblebicioglu H, Pshenichnaya N, et al. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. Int J Infect Dis. 2017;58:82-9.
3. Leblebicioglu H, Ozaras R, Fletcher TE, Beeching NJ, ESCMID Study Group for Infections in Travellers and Migrants (ESGITM). Crimean-Congo haemorrhagic fever in travellers: A systematic review. Travel Med Infect Dis. 2016;14(2):73-80.
4. Yilmaz G, Koksal I, Topbas M, Yilmaz H, Aksoy F. The effectiveness of routine laboratory findings in determining disease severity in patients with CrimeanCongo hemorrhagic fever: severity prediction criteria. J Clin Virol. 2010;47(4):361-5.
5. Kilinc C, Gückan R, Capraz M, Varol K, Zengin E, Mengeloglu Z, et al. Examination of the specific clinical symptoms and laboratory findings of Crimean-Congo hemorrhagic fever. J Vector Borne Dis. 2016;53(2):162-7.
6. Dreshaj S, Ahmeti S, Ramadani N, Dreshaj G, Humolli I, Dedushaj I. Current situation of Crimean-Congo hemorrhagic fever in Southeastern Europe and neighboring countries: a public health risk for the European Union? Travel Med Infect Dis. 2016;14(2):81-91.
7. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect. 2006;12(6):551-4.
8. Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009;13(3):380-6.
9. Mostafavi E, Pourhossein B, Chinikar S. Clinical symptoms and laboratory findings supporting early diagnosis of Crimean-Congo hemorrhagic fever in Iran. J Med Virol. 2014 Jul;86(7):1188-92. 10. Owaysee Osquee H, Pourjafar H, Taghizadeh S, Haghdoost M, Ansari F. Laboratory features of 160 CCHF confirmed cases in Zabol of Iran: A 10-year study. J Infect. 2017;74(4):418-20.
11. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266(3):1926-33.
12. Eugen-Olsen J. suPAR - a future risk marker in bacteremia. J Intern Med. 2011;270(1):29-31.
13. Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Koksal I. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol. 2011;50(3):209-11.
14. Tanyel E, Sunbul M, Fletcher TE, Leblebicioglu H. Aetiology of PCR negative suspected Crimean-Congo hemorrhagic fever cases in an endemic area. Pathog Glob Health. 2016;110(4-5):173-7.
15.Büyüktuna SA, Doğan HO, Unlusavuran M, Bakir M. An evaluation of the different biomarkers to discriminate bleeding in Crimean-Congo hemorrhagic fever. Ticks Tick Borne Dis. 2019;10(5):997-1002.
16. Akinci E, Bodur H, Sunbul M, Leblebicioglu H. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antiviral Res. 2016;132:233-43.
17. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2.
18.Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. 2017;312:19-23.
19. Ostrowski SR, Plomgaard P, Fischer CP, Steensberg A, Møller K, Høyer‐Hansen G, et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol. 2005;61(2):197- 206.
20. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma Creactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
21. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004;36(1):14-9.
22. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis. 2005;191(8):1331-41.
23. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002;6(8):686-92.
24. Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(1):23-31.
25. Erkut N, Mentese A, Ozbas HM, Ermantaş N, Sümer A, Örem A, et al. The prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia. Turk J Haematol. 2016;33(2):135-40.
26. Karsen H, Cesur S, Karaağaç L, Binici I, Fidan Y, Oğüş E, et al. Can mannose-binding lectin and plasma level of soluble urokinase receptor be used in diagnosis and treatment monitorization of brucellosis patients? Mikrobiyol Bul. 2012;46(3):519-21.
27. Tsai PK, Tsao SM, Yang WE, Yeh CB, Wang HL, Yang SF. Plasma soluble urokinase-type plasminogen activator receptor level as a predictor of the severity of community-acquired pneumonia. Int J Environ Res Public Health. 2019;16(6):1035.
28. Nikkola A, Aittoniemi J, Huttunen R, Rajala L, Nordback I, Sand J, et al. Plasma level of soluble urokinase-type plasminogen activator receptor predicts the severity of acute alcohol pancreatitis. Pancreas 2017;46(1):77-82.
29. Huang Q, Xiong H, Yan P, Shuai T, Liu J, Zhu L, et al. The diagnostic and prognostic value of suPAR in patients with sepsis: A systematic review and metaanalysis. Shock. 2020;53(4):416-25.
30. Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, et al. Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis. Int J Tuberc Lung Dis. 2019;23(11):1155-61.

APA	Küçükceran K, Karaşahin Ö, delice o, Batur A, İba Yilmaz S, şebin e, Şenyurt M (2021). The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. , 15 - 19. 10.18678/dtfd.820602
Chicago	Küçükceran Kadir,Karaşahin Ömer,delice orhan,Batur Ali,İba Yilmaz Sibel,şebin engin,Şenyurt Mahmut The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. (2021): 15 - 19. 10.18678/dtfd.820602
MLA	Küçükceran Kadir,Karaşahin Ömer,delice orhan,Batur Ali,İba Yilmaz Sibel,şebin engin,Şenyurt Mahmut The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. , 2021, ss.15 - 19. 10.18678/dtfd.820602
AMA	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. . 2021; 15 - 19. 10.18678/dtfd.820602
Vancouver	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. . 2021; 15 - 19. 10.18678/dtfd.820602
IEEE	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M "The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department." , ss.15 - 19, 2021. 10.18678/dtfd.820602
ISNAD	Küçükceran, Kadir vd. "The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department". (2021), 15-19. https://doi.org/10.18678/dtfd.820602

APA	Küçükceran K, Karaşahin Ö, delice o, Batur A, İba Yilmaz S, şebin e, Şenyurt M (2021). The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. Düzce Tıp Fakültesi Dergisi, 23(1), 15 - 19. 10.18678/dtfd.820602
Chicago	Küçükceran Kadir,Karaşahin Ömer,delice orhan,Batur Ali,İba Yilmaz Sibel,şebin engin,Şenyurt Mahmut The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. Düzce Tıp Fakültesi Dergisi 23, no.1 (2021): 15 - 19. 10.18678/dtfd.820602
MLA	Küçükceran Kadir,Karaşahin Ömer,delice orhan,Batur Ali,İba Yilmaz Sibel,şebin engin,Şenyurt Mahmut The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. Düzce Tıp Fakültesi Dergisi, vol.23, no.1, 2021, ss.15 - 19. 10.18678/dtfd.820602
AMA	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. Düzce Tıp Fakültesi Dergisi. 2021; 23(1): 15 - 19. 10.18678/dtfd.820602
Vancouver	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department. Düzce Tıp Fakültesi Dergisi. 2021; 23(1): 15 - 19. 10.18678/dtfd.820602
IEEE	Küçükceran K,Karaşahin Ö,delice o,Batur A,İba Yilmaz S,şebin e,Şenyurt M "The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department." Düzce Tıp Fakültesi Dergisi, 23, ss.15 - 19, 2021. 10.18678/dtfd.820602
ISNAD	Küçükceran, Kadir vd. "The Diagnostic Value of Soluble Urokinase Plasminogen Activator Receptor in Crimean-Congo Hemorrhagic Fever Disease in the Emergency Department". Düzce Tıp Fakültesi Dergisi 23/1 (2021), 15-19. https://doi.org/10.18678/dtfd.820602